Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model.

Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol (2000) 2.51

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37

Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29

Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc (2014) 2.07

Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer (2005) 2.02

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol (2013) 1.75

Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol (2009) 1.67

Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol (2004) 1.48

Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer (1998) 1.36

A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res (2009) 1.25

Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol (2011) 1.25

Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica (2003) 1.20

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia (2007) 1.18

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer (2003) 1.18

Strain-dependent variation in collateral circulatory function in mouse hindlimb. Physiol Genomics (2010) 1.18

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res (2004) 1.15

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One (2012) 1.14

Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10

Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood (1997) 1.05

Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia (2001) 1.05

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol (2000) 1.00

Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica (2008) 0.98

High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol (2007) 0.97

Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res (2003) 0.97

Osteonecrosis in stroke-prone spontaneously hypertensive rats: effect of glucocorticoid. J Orthop Sci (2007) 0.96

PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol (2001) 0.91

High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med (2013) 0.90

Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol (2013) 0.89

Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer (2014) 0.87

Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy. Eur J Pediatr (1989) 0.85

Substrain-specific differences in survival and osteonecrosis incidence in a mouse model. Comp Med (2012) 0.85

L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost (2008) 0.83

Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit (2006) 0.82

Early arteriopathy and postulated pathogenesis of osteonecrosis of the femoral head. The intracapital arterioles. Clin Orthop Relat Res (1992) 0.82

Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol (2015) 0.80

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS One (2015) 0.76

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS One (2015) 0.76